Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | AGXT | P21549 | 2/20 | 0.46 |
| ▸ | APP | P05067 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5229745 | 1.00 | CA1 (0.54) | CA1CA2IDO1AGXTAPP | |
| SCHEMBL7190391 | 1.00 | CA1 (0.54) | CA1CA2IDO1AGXTAPP | |
| SCHEMBL3545056 | 0.82 | CA1 (0.53) | CA1CA2IDO1AGXTAPP | |
| SCHEMBL13547256 | 0.82 | CA1 (0.53) | CA1CA2IDO1AGXTAPP | |
| SCHEMBL3545052 | 0.82 | CA1 (0.53) | CA1CA2IDO1AGXTAPP | |
| SCHEMBL121000 | 0.81 | TSHR (0.50) | CA1CA2HTTTSHR | |
| SCHEMBL5228321 | 0.81 | TSHR (0.50) | CA1CA2HTTTSHR | |
| SCHEMBL7627184 | 0.81 | TSHR (0.50) | CA1CA2HTTTSHR | |
| SCHEMBL12770589 | 0.81 | CA1 (0.55) | CA1CA2IDO1AGXTAPP | |
| SCHEMBL2608864 | 0.80 | CA1 (0.62) | CA1CA2IDO1AGXTAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915306-B2 | For therapy of inflammatory or autoimmune disorders | EISAI CO., LTD. (JP) | 2011-03-29 | — | — | US | disclosed |
| US-7799827-B2 | Macrocyclic compounds useful as pharmaceuticals | EISAI CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-7700783-B2 | Synthesis of discodermolide and variants thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-04-20 | — | — | US | disclosed |
| US-7645782-B2 | Thia-epothilone derivatives for the treatment of cancer | Richter, Wolfgang (DE) | 2010-01-12 | — | — | US | disclosed |
| US-7645782-B2 | Thia-epothilone derivatives for the treatment of cancer | Richter, Wolfgang (DE) | 2010-01-12 | — | — | US | disclosed |
| US-7645782-B2 | Thia-epothilone derivatives for the treatment of cancer | Richter, Wolfgang (DE) | 2010-01-12 | — | — | US | disclosed |
| EP-1567524-B1 | THIA-EPOTHILONE DERIVATIVES FOR THE TREATMENT OF CANCER | RICHTER WOLFGANG (DE) | 2009-07-22 | — | — | EP | disclosed |
| US-7553859-B2 | Macrocycles for the treatment of cancer | Richter, Wolfgang (DE) | 2009-06-30 | — | — | US | disclosed |
| US-7553859-B2 | Macrocycles for the treatment of cancer | Richter, Wolfgang (DE) | 2009-06-30 | — | — | US | disclosed |
| US-7553859-B2 | Macrocycles for the treatment of cancer | Richter, Wolfgang (DE) | 2009-06-30 | — | — | US | disclosed |
| EP-1567524-A1 | THIA-EPOTHILONE DERIVATIVES FOR THE TREATMENT OF CANCER | Richter, Wolfgang (DE) | 2005-08-31 | — | — | EP | disclosed |
| EP-1521752-A1 | NOVEL MACROCYCLES FOR THE TREATMENT OF CANCER | Gesellschaft fur Biotechnologische Forschung mbH (gbf) (DE) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004048372-A1 | THIA-EPOTHILONE DERIVATIVES FOR THE TREATMENT OF CANCER | MORPHOCHEM AG KOMB CHEMIE (DE) | 2004-06-10 | — | — | WO | disclosed |
| US-20040073049-A1 | Process for preparing intermediates for the manufacture of discodermolide and discodermolide analogues | NOVARTIS AG (CH) | 2004-04-15 | — | — | US | disclosed |
| WO-2004007492-A1 | NOVEL MACROCYCLES FOR THE TREATMENT OF CANCER | GESELLSCHAFT FUER BIOTECHNOLGISCHE FORSCHUNG MBH (GBF) (DE) | 2004-01-22 | — | — | WO | disclosed |
| EP-1368334-A2 | PROCESS FOR PREPARING INTERMEDIATES FOR THE MANUFACTURE OF DISCODERMOLIDE AND DISCODERMOLIDE ANALOGUES | Novartis AG (CH) | 2003-12-10 | — | — | EP | disclosed |
| WO-2003080567-A2 | INTERMEDIATES FOR THE SYNTHESIS OF DISCODERMOLIDE AND RELATED ANALOGUES AND METHODS FOR THEIR PREPARATION | NOVARTIS AG (CH) | 2003-10-02 | — | — | WO | disclosed |
| US-20030134883-A1 | 14-Methyl-epothilones | KOSAN BIOSCIENCES,INC. | 2003-07-17 | — | — | US | disclosed |
| WO-2003045324-A2 | 14-METHYL-EPOTHILONES | KOSAN BIOSCIENCES, INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| WO-2002057251-A2 | PROCESS FOR PREPARING INTERMEDIATES FOR THE MANUFACTURE OF DISCODERMOLIDE AND DISCODERMOLIDE ANALOGUES | NOVARTIS AG (CH) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134883-A1 | 14-Methyl-epothilones | DNMT1, TET1, MYC | CA1 4628/4885CA2 4620/4885IDO1 3539/4885 |
| US-20040073049-A1 | Process for preparing intermediates for the manufacture of discodermolide and discodermolide analogues | DHPS, DHCR7, EML4 | CA1 4491/4885CA2 4682/4885IDO1 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.